Tumour heterogeneity describes the coexistence of divergent tumour cell clones within tumours, which is often caused by underlying epigenetic changes. DNA methylation is commonly regarded as a significant regulator that differs across cells and tissues. In this study, we comprehensively reviewed research progress on estimating of tumour heterogeneity. Bioinformatics-based analysis of DNA methylation has revealed the evolutionary relationships between breast cancer cell lines and tissues. Further analysis of the DNA methylation profiles in 33 breast cancer-related cell lines identified cell linespecific methylation patterns. Next, we reviewed the computational methods in inferring clonal evolution of tumours from different perspectives and then proposed a deconvolution strategy for modelling cell subclonal populations dynamics in breast cancer tissues based on DNA methylation. Further analysis of simulated cancer tissues and real cell lines revealed that this approach exhibits satisfactory performance and relative stability in estimating the composition and proportions of cellular subpopulations. The application of this strategy to breast cancer individuals of the Cancer Genome Atlas's identified different cellular subpopulations with distinct molecular phenotypes. Moreover, the current and potential future applications of this deconvolution strategy to clinical breast cancer research are discussed, and emphasis was placed on the DNA methylation-based recognition of intra-tumour heterogeneity. The wide use of these methods for estimating heterogeneity to further clinical cohorts will improve our understanding of neoplastic progression and the design of therapeutic interventions for treating breast cancer and other malignancies.
Introduction
Human cancers contain a mosaic of cellular subclones with varying population proportions, different genetic/epigenetic makeups and distinguishable phenotypic features. This intratumour heterogeneity might drive cancer progression and therapeutic resistance [1] . In many aspects of laboratory research and particularly in cancer research, established human cell lines are extensively applied for molecular diagnosis as experimental models to identify important molecular events and drug targets. Theodora et al. found that in vitro human cell lines can reliably predict clinical utility [2] . Gazdar et al. compared the characteristics of established breast cancer and lung cancer cell lines with the corresponding tumours from which they were isolated [3] [4] [5] . Good concordance was observed, and the cell lines retained the properties of their parental tumours and provided suitable model systems for biomedical studies.
The National Cancer Institute assembled a set of 60 human cancer cell lines from nine common cancer types, and this set of cell lines has been used extensively in cancer studies [6] . Cultures of the primary hepatoma cell line HepG2 are frequently used as in vitro models for human biotransformation studies [7] . Gottschling et al. showed essential genetic similarities between lung cancer cell lines and their corresponding tumour tissues using comparative genomic hybridization and multiplex fluorescence in situ hybridization [8] . In previous breast cancer studies, MCF7 cells have been widely used in ER-positive cell experiments [9] , whereas MDA-MB-231 serves as a highly metastatic cell line. The integrated study of 51 breast cancer cell lines reported by Neve et al. considered that these cell lines mirrored both the genomic heterogeneity and the recurrent genome copy number abnormalities found in primary tumours with high fidelity [10] . In addition, the cancer cell lines and breast tumours always shared substantial global similarities in their transcriptome structures [11] . Cope et al. found that the DNA methylation profiles of breast cancer cell lines largely retain the features that characterize primary tumours [12] . Therefore, cancer cell lines can feasibly be used to evaluate cancer tissue heterogeneity.
Recent studies have also shown that DNA methylation might play an important role in the development of cancers [13] . An integrated analysis of DNA methylation in 27 gene promoters and the corresponding gene expression suggested that methylation was more strongly associated with clinical parameters than gene expression [14] . It is known that DNA methylation varies among cell types within certain tissues, and aberrant DNA methylation has long been thought to play an important role in tumourigenesis and cancer progression [15] [16] [17] . The degree of tissue methylation represents an average of the methylation in all existing cell types [18] . However, the average methylation may render the interpretation of methylation differences among these cancer tissues difficult because the proportions of specific cell types vary among tissues. Cell-type-specific methylation signatures are preserved in cancer cell lines and tissues, and DNA methylation can be used as a sensitive and specific biomarker for diverse cell types [19, 20] . Thus, the identification of differences in cell-specific methylation within tissues might improve our understanding of the epigenetic regulation of cancer tissue celltype-specific functions. Together, these findings suggest that DNA methylation can be used as a cell subclonal molecular feature to simultaneously assess and quantify multiple cell types in complex cancer mixtures [21] .
Currently, estimation of the composition of a tumour sample always focuses on two aspects, tumour purity as well as the number and fractions of tumour cell subpopulations. However, methods to determine these always explicitly require deeply sequenced data [22, 23] . Thus, these strategies are not amenable to less expensive low-coverage sequence data or TCGAgenerated microarray data [24] . Given this, we summarized the global phylogenetic relationship between breast cancer cell lines and tumour tissues based on HumanMethylation450 data and reviewed the cell-type-specific methylated genes in these cell lines. Furthermore, we made use of the aforementioned cell-type-specific genes to explain the intra-tumour heterogeneity in TCGA breast tumour tissues from a new perspective considering both tumour purity and the cancer cell subclones. It is worth noting that the heterogeneity owing to the cell subpopulations was inseparably related to clinical prognosis. This article deepens our understanding of intra-and inter-tumour heterogeneity and will provide new insights that can be applied to individualized treatment.
Materials and methods

DNA methylation data sets
Genome-wide DNA methylation profiles in 39 breast cancer cell lines and 4 normal breast cell lines (two HMEC and two MCF10A cell lines) contained in five data sets were downloaded from Gene Expression Omnibus (GEO) database at the National Center for Biotechnology Information (NCBI) [25, 26] . Breast cancer tissues were available at the GEO database under the accession number GSE39004 [27] ; this set contained 62 cancer tissues obtained from solid tumours. Another data set from the Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov/) was obtained; this data set comprised a breast cancerous population (n ¼ 684) and a normal population (n ¼ 96) [28] . The DNA methylation profiles were analysed using an Infinium HumanMethylation450 BeadChip containing >480 000 probes covering 99% of NCBI reference sequence genes [29] , thereby providing single cytosine-guanine (CpG) resolution on DNA methylation. Single nucleotide polymorphism (SNP) probes and CpH (A/T/C) sites were eliminated from the further analysis, and 482 421 CpG sites remained.
Phylogenetic tree construction
A phylogenetic tree was generated to assess the tumour evolutionary patterns in terms of DNA methylation. DNA methylation Euclidean distance matrices were calculated using all CpG sites among the 43 cells and 62 breast cancer tissues obtained from GSE39004. The 'fastme.bal' function in the R package 'ape' was used to infer methylation-based phylogenetic trees based on the minimal evolution algorithm [30] . In addition, the phylogenetic relationships between cells and every cancer tissue were individually concluded.
Identification of cell line-specific methylated genes
Among the 43 cell lines, 26 different cell lines under the accession number GSE44837 and 7 distinct cell lines from the other data sets that were nonredundant with the 26 cell lines in GSE44837 were selected to identify specific methylated genes for each cell line. Altogether, 33 breast cell lines including 31 cancer cells and 2 normal cells (HMEC and MCF10A) were selected. This selection strategy might avoid the influences caused by batch effects to the greatest extent. Genes located in sex chromosomes or only containing a single CpG site were eliminated in the following analyses. For each gene, we constructed 33 different linear mixed effects (LME) models based on all CpG sites within the genes corresponding to 33 cell lines using residual maximum likelihood (REML) criterion-fitting models [31] . In the following LME model, cell types were designated as fixed effects, and CpG sites were designated as random effects.
For the 33 LME models corresponding to the 33 selected cell lines, we denoted fixed factor cell types as cell lines c k and the remaining cell lines as nc k , and explored methylation differences between c k and nc k . In the above equation, y represents the DNA methylation of a gene, l cell is the fixed effect by which a different cell influences y and a CpG is the random effect by which CG sites within the gene influence y. The value of the fixed effect, which was regarded as the fixed factor, mainly influenced the gene's DNA methylation, indicating the methylation level of each gene inherent for a given cell. For a gene, the LME model that fits the data best indicates that the methylation of a gene in cell-type k was more specific compared with that in other cell lines. We applied the lmer function implemented in the R package 'lme4' to fit the 33 models for each gene using the REML criterion.
For each gene, the Akaike information criterion (AIC) value and the weight of each linear mixed model were calculated according to the following formula [32] .
Here, D k ðAICÞ ¼ AIC k À minAIC, and the weight values lie in the range from 0 to 1. A weight value closer to 1 indicates that the AIC value is smaller, whereas a weight value close to 0 indicates that the AIC value of the model differs more greatly from the minimum value of AIC. The data always support the model with the smallest AIC value and the largest weight value. For each gene, 33 AIC values representing the relative quality and weights representing the probability of every linear model were calculated and compared, respectively. Only genes belonging to the model for which the weight value was equal to the maximal value 1 were considered cell-type-specific genes.
Statistical deconvolution of cell-type-specific subpopulation patterns Suppose a tumour tissue comprises diverse tumour and normal cells. In this article, we adopted a supervised analysis to predict the cell subgroup and the corresponding content in each breast cancer sample based on the methylation level of the breast cells. Methylation values y i are assumed for the evaluated sample, where gene i ¼ 1,2. . .n, and assumes the methylation levels X ¼ x ik for gene i and for the deconvolution cell types k ¼ 1,2,. . .,K. For each evaluated sample, the linear regression model was trained as follows:
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Where b k was the composition proportion for cell k in the sample, and e i was the random error. We performed quadratic programming (QP) to fit the linear model [33, 34] , generating a coefficient of each cell that satisfied the following conditions:
The solve.QP function implemented in the R package 'quadprog' was performed to obtain the proportion of each cell in each sample. Only if the cellular proportion exceeded a specified value (set as 0.00001 here), would the cell be reserved. Then, the cells that were most significantly correlated with the evaluated sample were screened out based on a partial least squares (PLS) analysis.
Where d k denotes the explanation extent of cell k for the sample, and e i denotes a random error term, which is assumed to follow a normal distribution N (0, 0.01). We applied the R package 'pls' for PLS analysis to train the linear regression model, and the significance of the effect of the independent variables on the dependent variable was estimated using leaveone-out cross-validation. To avoid problems associated with overfitting, the number of subpopulations for which the prediction error sum of squares was least or no longer changed was selected for use in the final model. In addition, the jack.test function was used to test the statistical significance of the regression coefficient, and subclone cell groups with significant P-values (P < 0.01) were conserved.
Simulated data
Tissue samples with 1-33 cell subpopulations were simulated to evaluate the predicted power and robustness for the approach described above. Cells with constant numbers were randomly selected, and the proportion of each cell was determined stochastically (the sum of these proportions was 1). Methylation data were simulated for the samples using the following formula:
Where, q k represents the proportion of the cell-type k (range 0 to 1) and P q k ¼ 1. H is the number of cells used to the simulate samples, H ¼ 1, 2,. . ., 33. The independent variable x ik refers to the methylation level of cell k and gene i; e i is the random error with N (0, 0.01) and c i is the methylation level of gene i for the simulated sample. Each situation that contained the same number of cells simulated for the cancer tissues was repeated for 1000 times, and our method was used to evaluate the cell subpopulations and to quantify the proportions based on the simulated data. A receiver operating characteristic (ROC) curve was plotted for each situation, and the area under the curve (AUC) was calculated; other situations were selected as a negative control. The simulations and statistical analyses were performed using R v3.0.1.
Estimation of false discovery rate for cellular subclone population prediction
To estimate the false discovery rate (FDR) for the cell subpopulation proportion analysis, we fixed the methylation levels for each cell and permuted the labels of the cells to yield a new sample by multiplying the predicted cell proportions 10 000 times. Correlations between the new sample and the given sample were calculated. In each case, we estimated FDR by dividing 10 000 by the number of samples that exceeded the correlation coefficient of the methylation level between the predicted and evaluated samples. This yielded an estimated FDR for each evaluated individual. Samples for which FDR was >0.01 were excluded.
Consensus clustering
Consensus clustering [35] method provided quantitative and visual stability evidence for estimating the number of unsupervised classes in a data set and was performed using the ConcensusClusterPlus [36] package in R to determine subgroups of breast tumours based on the cell subpopulations of the samples. Each subsample was then partitioned into 2-20 groups using the k-means clustering algorithm with the Euclidean squared distance metric. This process was repeated 100 times, and the stability of each clustering was determined based on the empirical cumulative distribution function (CDF). We chose the minimum number of clusters for which the relative change in area under the CDF curve was almost constant, indicating a maximum stability.
Survival analysis for the consensus clusters
Kaplan-Meier plots were used to illustrate overall survival among the breast tumour clusters as defined by cell subpopulations and to test whether the clusters differed significantly in survival. The significance of differences in survival between the nine clusters was estimated using the log-rank test. Survival analysis was carried out using the R package, 'survival'.
Model robustness for predicting breast cancer subclusters
As a successful ensemble learning classifier, the random forest method was adopted to predict breast cancer subclusters based on breast tumour cellular composition using the R package 'randomForest'. Here, for each cluster, we randomly sampled the same number of data from other clusters as a negative data set to avoid bias caused by an unbalanced proportion of positive and negative data sets; model accuracy was estimated by performing 10-fold cross validation. The proposed method is available as an open-source R package on GitHub at https://github. com/Kinspact/BCheterogeneity/.
Results
The evolutionary relationship between breast cancer cell lines and tissues
Breast cancer is historically one of the most prevalent malignancies, and genetically and epigenetically divergent cell subclones coexist within tumours. In general, cancer tissues are heterogeneous owing to the presence of different cell subclone groups that have evolved from a single progenitor population survived in the tumour microenvironment [37] . Even after lengthy periods of cultivation, breast cancer cell lines in vitro are likely to largely reflect the features of cancer cells in vivo [38] . Cancer cell lines always retain the properties of the parental tumours. Patterns of DNA methylation, which occur at discrete CpG dinucleotide sites, are known to regulate tissue-specific gene expression and can be used as sensitive and specific biomarkers for diverse cell types. To comprehensively review the potential association between breast cancer tissues and cell lines at the DNA methylation level, we collected as many breast cell lines as possible from the same platform. DNA methylation data for breast cell lines were obtained from the GEO and ENCODE databases, which contain 43 breast normal and cancer cell lines (Table 1) , whereas breast cancer tissues were obtained from the GEO database, which includes 62 solid tumours.
We further inferred phylogenetic relationships based on pairwise distances of the entire genome methylation profiles among these cell lines and cancer tissues. The phylogenetic tree topology based on global DNA methylation is presented in Figure 1A . The evolutionary relationships among the different cancer samples or different cell lines were closer than those between the cell lines and cancer samples, whereas the phylogenetic relationships between the cell lines were more distant than those between the cancer samples. In addition, we found that the methylation levels of the breast cancer cell lines spanned a wider distance than did those of the breast cancer tissues ( Figure 1B ). Methylation levels in the breast cancer cell lines tended towards hyper-methylation and hypo-methylation when compared with the breast cancer tissues. The medium level of methylation found in the breast tissues might be owing to the high heterogeneity within tumours. Further informing our view of the phylogenetic relationship between each cancer sample and all cell lines, we found that each cancer sample had a shared evolutionary ancestry with several cells; three different situations are considered representative ( Figure 1C-E) . The left-hand panel illustrates the condition that the cancer sample and several cancer cells shared a common evolutionary ancestor; the centre panel illustrates the condition where the cancer sample shared a common ancestor with the normal cells; and the right-hand panel illustrates the condition where the cancer sample shared a common evolutionary precursor with both normal and cancer cells. All of these conditions suggest an inseparable relationship between cancer samples and cell lines based on the genome-wide DNA methylation profiling analysis. Breast cancer cell lines always reflected the characteristics of cancer cells in vivo, and tumour tissues shared a common evolutionary ancestry with cell lines. The genetic and epigenetic changes seen in cultured cell lines might also reflect the changes seen in vivo. Based on these findings, we proposed the hypothesis that the heterogeneity of tumour samples results from a blending of these heterogeneous normal and cancer-cell subgroups. In other words, we regarded the cancer cell lines as cell subpopulations existing within the cancer tissues. As shown in Figure 1F , different cell lines differed in their DNA methylation levels, whereas tissue samples that commixed with identical cells at different mixing ratios resulted in disparate DNA methylation. As an important epigenetic signature, DNA methylation is diacritical and representative of cell subpopulations and can reflect the heterogeneity of cancer tissues. Therefore, our method was designed to implement a deconvolution process based on the methylation of the given tissues and integrated cell lines to evaluate cell proportions within breast tissues ( Figure 1G ).
Table1: Breast cell lines for deconvolution and validation
GEO
Cell line-specific methylation patterns
Cell line-specific methylation patterns are preserved in cancer cell lines and tissues. Replicated cell lines grown in several laboratories display stable DNA methylation signatures [39] . Therefore, DNA methylation plays an important role in defining cell types, and different cell lines can exhibit different DNA methylation levels. Holm et al. found that different molecular subtypes of breast cancer harboured specific methylation patterns [40] . We summarized 11 previous studies, which suggested different DNA methylation patterns among breast cancer cell lines, containing 23 breast cell lines totally (Supplementary Table S1 ). To further describe the DNA methylation signatures that are specific for these established cell lines, we scanned each gene in 33 distinct unduplicated cell lines by constructing 33 LME models; in these analyses, cell line was regarded as a fixed effect (see the Materials and Methods section). Eventually, 2320 cell-type-specific DNA methylated genes were identified in all cell types (from 8 to 668, depending on the cell) ( Table 2 ). For instance, 308 specific genes were distributed in normal cell HMEC, whereas the cancer cell line T47D contained 21 genes.
The inherent methylation level of the genes, as influenced by cell type, was used as the value of the fixed effect produced by LME. The mean DNA methylation values of specific genes were calculated based on the presence of multiple CpGs within genes. Subsequently, a high correlation (r ¼ 0.9999, P-value ¼ 0) between the fixed effect values and the average methylation levels of these cell-type-specific genes was observed (Figure 2A ). This finding suggested that the average level of methylation might also reflect inherent cellular methylation and that celltype-specific gene methylation might be a stable cell feature. Simultaneously, the average methylation of each cell linespecific genes might be ideally used to separate one cell type from other cell types ( Figure 2B and Supplementary Figure S1 ). Furthermore, we compared the DNA methylation of these celltype-specific methylated genes between breast cancer cell lines and solid tumours (Supplementary Figure S2) . A clear difference existed, and this difference was especially evident in the cell that these genes were specific to. Consequently, we considered the mean methylations of 2320 genes to be stable features of 33 cell types.
Gene Ontology and Kyoto Encyclopedia of Genes and Genomes functional enrichment analyses were then carried out using DAVID Functional Annotation Bioinformatics Microarray Analysis (http://david.abcc.ncifcrf.gov/home.jsp) in allusion to the gene sets that were specific for each cell line. The most significant five functions and pathway catalogues for each cell line are shown in Figure 2C . We found that the gene sets that were specific for each cell line had characteristic functions and biological pathways that distinguished them from other cell lines, indirectly reflecting the methylation signature of each cell line. Therefore, the methylation signature of these genes can serve as sensitive and specific biomarkers for the evaluation of cellular subpopulations.
Methods for estimating the composition of breast tumours
Estimating the composition of the tumour tissues, including not only the tumour purity but also the number and proportions of the subpopulations of tumour and normal cells might accelerate our understanding of tumour progression and contribute to the development of treatment strategies [41, 42] . In recent years, several computational methods have been developed to infer the population structure of heterogeneous tumours. These methods are generally based on single-nucleotide variants (SNVs) [22, 23, [43] [44] [45] , copy number aberrations (CNVs) [24, [46] [47] [48] [49] [50] [51] [52] , mutations [53] , gene expression [54] [55] [56] or DNA methylation [57, 58] and evaluate the tumour composition from diverse angles using different techniques (Table 3 ). In particular, the identification of specific molecular features for cell subclonal populations in tumour tissues is meaningful for the deconvolution of tumour heterogeneity. After a comprehensive review of previous studies, a linear regression model based on PLS and QP was proposed in Methods, and this method was used to analyse the relationships between cancer tissues and cell types in terms of their composition. Using statistical deconvolution, the cells most likely to exist in cancer tissues were identified and their proportions were determined. To evaluate the power and robustness of our linear regression model, we applied our method to predict the cell composition and proportions in simulated tumour samples comprising several cell types (Materials and methods). ROC curves exhibiting superior power values in different situations were plotted with the corresponding AUC values > 0.88 ( Figure 3A) . Meanwhile, the predicted proportions of the cells were in near-perfect agreement with the simulated proportions, and the results achieved high-level statistical significance (cor ¼ 0.9981, P ¼ 0; Figure 3B ). Additionally, a certain degree of bias was found regarding the number of specific genes in different cell lines (Table 2 ). Three extreme situations that were simulated with two cells possessing the minimum or maximum numbers of cell-type-specific genes were selected for simulated evaluation 1000 times, respectively. All situations were predicted correctly, and a high degree of correlation was found between the generated and predicted coefficients of proportionality (Supplementary Figure S3) . Consequently, the performance achieved using our method would not be affected by the number bias of specific genes or other stochastic disturbance. These indications directly implicate and establish the power of this method to quantitatively reconstruct the precise makeup of cellular mixtures and their biological interpretation based on PLS and QP.
To further validate our model by estimating the simplex ratio, we applied our deconvolution strategy to an additional 10 real cell line samples (Table 1) . Each cell line was predicted accurately ( Figure 3C ). Among the cell lines, normal cells HMEC and MCF10A were correctly predicted as its real property up to 99.57% and 97.33%, respectively. Seven cells were predicted with accuracy >78%. Although the predicted purity of one cancer cell line was relatively poor (MDAMB231, 65%), which might be because of the force majeure factors during cell culture, our predicted results indicated a strong cellular recognition ability. This implies that the cell-type-specific genes that were identified by our model were specific to each kind of cell and had a strong ability of cell separation and identification, providing a credible forecast achievement.
Cellular subpopulations differences in breast tumours
It is increasingly evident that tumour heterogeneity is one of the underlying causes of resistance to systemic therapies and differences in prognosis. Although originating from a single cell, breast cancer is heterogeneous, comprising cell types with distinct morphologies and behaviours owing to stress from the cancer microenvironment [59] . Reconstructing their evolutionary histories and characterizing the subclonal groups are therefore necessary. Consequently, we applied our method to a cancerous population including 684 tissues from TCGA. Strong heterogeneity was found among the samples, as they exhibited different cellular composition and proportions (Supplementary Figure S4) . In accordance with previously published studies, diverse cancer subclonal cell populations coexisted with normal breast cells with unknown percentages in cancer tissues [46, 60] . Interestingly, normal cells always existed and formed a large proportion (mean 41%) of cancer samples; cancer cells were present at approximately 42%. Even though we could not explain the repertoire of each sample, the total predicted percentage was as high as 80%. This might be attributed to the lack of the types of cancer cell. Moreover, the deconvolution process was further performed on the normal population contained 96 tissues from TCGA as control. Normal tissues and solid tumours differed significantly in composition and proportions of normal and cancer cells ( Figure 4A and B) . Normal samples contained a higher percentage of normal cells (mean ¼ 73%) than cancer samples (mean ¼ 41%) using t-test (P ¼ 2.48e-98). Therefore, our method was able to significantly distinguish solid tumours from normal tissues based on the proportions of normal and cancer cells. Among the 96 normal samples, 90 were normal matched tissues to the 684 cancer tissues. We further compared the proportion of normal cells between normal and tumour tissues from the same patients. Most patients showed a significantly higher proportion of neoplastic cells and a lower proportion of normal cells in cancer tissues in comparison with the adjacent normal tissues (Supplementary Figure S5) . It is natural that a certain amount of cancer cells were predicted in normal tissues. The capacity of cancer cells to migrate and invade neighbouring tissue permits them to migrate within tissues [61] . Neoplastic cells can infiltrate neighbouring tissues through the surrounding tissues and lymphatic and blood vessels [62] . Although cancer cells had not been found to have migrated via the traditional pathology testing, cancer cells had already entered into the normal tissues, representing the early signs in tumour progression. These results indicate that our method was useful for the evaluation of tumour heterogeneity and provided credible results.
Cellular subpopulations and distinct molecular phenotypes
Specific subpopulation exhibited distinct molecular phenotypes. As a complex heterogeneous disease, breast cancer comprises several major subtypes that are characterized by different molecular alterations and clinical outcomes [63, 64] . The main breast cancer subtypes exhibit significant differences in response to docetaxel and paclitaxel-and doxorubicin-containing preoperative chemotherapies [65, 66] . Seventy-five percent of breast cancer patients are estrogen receptor positive and receive endocrine therapy; however, approximately one third of these patients eventually develop endocrine resistance and experience cancer recurrence [67] . As an important clinical problem, resistance to endocrine therapy in breast cancer urgently needs to be addressed. New therapeutic strategies to overcome this resistance will be developed only when we clearly understand this extremely complicated scenario. Currently, the expansion of genetically distinct sub-clonal populations might aid in the interpretation of the emergence of drug resistance [68] . The elaborate classification of breast cancer might reflect the biological behaviour of tumours with greater accuracy. To review the overall features of breast tumours with similar cellular composition, consensus clustering was performed based on the tumour composition and cell proportions. Controlling for FDR < 0.01 (See Materials and methods), 12 TCGA cancer samples were eliminated from the consensus clustering analysis ( Figure 4C ). As illustrated in Figure 4D , nine distinct clusters of breast tumours were determined by consensus clustering when the approximate maximal CDF was selected as the criterion. Cell composition profiles for the nine clusters exhibit different demographic and composition preferences ( Figure 4E ). The Kruskal-Wallis rank sum test was performed to test the statistical significance of differences of the mean cell composition among the nine clusters (Supplementary Table S2 ). In particular, cluster 1 contained the highest proportions of HCC1500 and MDAMB415 and the lowest proportion of HCC38 cells compared with the other eight clusters. Cluster 2 contained a high proportion of ZR-75-30 and ZR-75-1 cells; cluster 3 presented higher proportions of HCC1500, MDAMB415 and normal cells; and cluster 4 presented the highest proportion of normal cells.
The hypergeometric test was applied to determine the significance of the enrichment of some clinical indicators, such as tumour size, lymph nodes, pathological tumour stage, metastasis, tumour grade, estrogen receptor (ER) status, progesterone receptor (PR) status and human epidermal growth factor receptor 2 (HER2) status ( Figure 5A and Supplementary Figure S6) . The P-values for multiple-testing correction were further adjusted using the FDR method. The clinical characteristics of the nine cellular subpopulation-defined tumour clusters differed. In particular, cluster 5 was specifically enriched in T1 tumour size, and cluster 8 was enriched in T2 tumour size, stage II, ER-negative and PR-negative statuses. Cluster 9, which was enriched in M1 distant metastasis, stage IV and HER2-negative status, suggested the worst prognosis of breast tumour. Clusters 2 and 7 both were enriched in ER-positive and HER2-positive statuses; in addition, cluster 1 was enriched in ER-positive status. Among these 672 samples within nine clusters, 212 samples were of known PAM50-defined subtypes, including Luminal A, Luminal B, basal-like, HER2-enriched and normal-like subtypes [28] (Supplementary Figure S7 and Table S3 ). Clusters 1 and 6 contained the largest proportion of luminal tumours (100%), followed by clusters 7 (95.23%), 9 (80%), 2 (84.21%), 5 (76.92%), 3 (66.67%), 4 (50%) and 8 (21.42%). For basal-like tumours, cluster 8 contained the highest proportion with 75%, followed by cluster 4 with 31.25%, cluster 9 with 20%, cluster 3 with 16.67%, cluster 5 with 15.38% and cluster 2 with 2.63%. The significance of the enrichment of PAM50 subtypes was determined using the hypergeometric test ( Figure 5B ). Cluster 8 was significantly enriched in basal-like subtype, whereas cluster 5 was specifically associated with the Luminal A subtype. Clusters 1, 6 and 7 were enriched in the Luminal B molecular subtype. Cluster 4 was specifically associated with the normal-like subtype. Recently, Wang et al. [69] developed a similarity network fusion method (SNFtool) to stratify the cancer subtypes based on TCGA data. Methylation data from HumanMethylation450, gene expression data from Illumina-HiSeq-RNASeq platform and microRNA (miRNA) expression data from Illumina-HiSeq-miRNASeq platform were used to classify the TCGA breast cancer samples (n ¼ 322) into five similarity network fusion (SNF) subtypes by SNFtool. As a consequence of data limitation, cluster 9 had no intersection with the 322 cancer samples used for classifying SNF subtypes. We determined the significance of the enrichment of SNF subtypes by the hypergeometric test as well, and found that cluster 8 was significantly enriched in SNF1 and SNF5 ( Figure 5C ). Cluster 1 was enriched in the SNF3 subtype, clusters 4 and 5 both were enriched in the SNF2 subtype, and clusters 2, 6 and 7 were enriched in the SNF4 subtype. It is not hard to see that our classification based on cellular composition and proportion was more detailed. In brief, these differential characteristics might partially explain the breast tumour heterogeneity.
Kaplan-Meier curves showing overall breast cancer survival also revealed differences between the nine breast tumour subgroups that were defined based on cell subclonal composition (log-rank P ¼ 0.00303; Figure 5D ). It is suggested that the consensus clustering based on cell composition was significantly correlated with clinical prognosis. Cluster 3, which contained a lower proportion of cancer cells (mean ¼ 32.96%, n ¼ 62) presented better survival than the other eight clusters. Clusters 1, 6 and 7, which had higher proportions on average (55.13%, 54.79% and 57.42%, respectively) of cancer cells, all resulted in poor prognosis. Specially, cluster 7 had the highest proportion of MDAMB175 VII, cluster 6 had the highest proportion of HCC1419 and cluster 1 had the highest proportion of HCC1500. This difference owing to the subclassification based on heterogeneous cellular subpopulations might explain why the samples had differential prognoses even though they belonged to the same molecular subtype. The random forest was used to validate our classification efficiency by 10-fold crossvalidation; the AUC values for nine clusters were high, suggesting that the classification performance depended on cell subpopulation ( Figure 5E ). Thus, the heterogeneity of cell subpopulations between the cancer samples could be used as a vital marker for breast cancer reclassification. 
Discussion
Recent studies have highlighted the tremendous complexity and heterogeneity between patients with the same breast cancer histopathological phenotype [70] . Inter-heterogeneity within tumour tissues can not only complicate definitive diagnosis but also obstruct therapeutic decision-making. At diagnosis, breast cancers comprise heterogeneous populations of tumour cells. This intra-tumour heterogeneity of cellular phenotypes, which results from genetic and epigenetic influences, can further pose a formidable barrier to cancer therapy and influence the evolutionary trajectory of cancers, similar to inter-tumour heterogeneity [71] . This article describes a retrospective review of the recent studies that evaluated tumour heterogeneity at different data levels. To further understand the heterogeneity within tumour tissues based on the established cell lines, we reviewed DNA methylation data for commonly used cell lines from the same platform and elucidated the phylogenetic relationships between these cell lines and solid tumours. Each solid tumour shared a common evolutionary ancestor with one or more cell lines. Because these cell lines can offer an infinite supply of a relatively homogeneous cell population [72] , we supposed these cell lines comprise the cell subpopulations existing in the cancer tissues. As DNA methylation is a crucial marker for defining cell types, we then reviewed the cell line-specific DNA methylation signatures in each cell line. These cell-type-specific genes could significantly distinguish the cells from the each other. Finally, the resource integration of these specific methylation signatures was combined to deconvolve the cell composition and proportions using a linear regression model. Finally, we reviewed the different molecular subtypes that were defined by the heterogenous cell composition and proportions. Although some cellular subpopulation phenotypes were heterogeneous within new tumour subclusters, the nine identified subclusters showed significant survival differences. This finding confirmed that the intrinsic subtype might be a major determinant of the intratumour heterogeneity distinguished by some epigenetic markers. Our deconvolution strategy can be used to explore the heterogeneous cell composition and proportions in various breast cancer tissues. Different cell composition and proportions can lead to differences in prognosis and clinical response. Despite exhibiting tumours with same composition and varying proportions or with differential composition and identical proportions, patients might exhibit distinct clinical pathological features and treatment responses. The recognition of intra-tumour heterogeneity will improve our understanding of neoplastic progression and aid the design of therapeutic interventions.
Human cell line models have been widely used in cancer studies to predict clinical responses and to study variations in drug responses in vitro [73] . Although questions have been raised about how representative immortalized cell lines are of human breast cancers, when used in the correct way, these cell lines remain powerful experimental tools. On several occasion, information derived from cell lines has translated into clinical benefits. Thus far, deciding how to choose an available cell line as an experimental model has always been a nasty puzzle for researchers. This work might provide an optimization strategy for selecting an appropriate cell line to study specific subgroups of breast cancer. Researchers can select one or more cell lines as experimental models by synthesizing our predicted cellular subpopulation for a specific research population. For example, HCC1937 (a human basal-like breast cancer cell line) presented at higher proportion in cluster 8, which was significantly enriched in basal-like subtypes, than that in other subclusters, as defined by the cellular population. However, focusing only on the HCC1937 cell line when studying cluster 8 or basal-like breast tumours might be insufficient because other cellular populations might exist in these cancer tissues. Therefore, a preliminary observation of the cellular status within cancer tissues using our method is meaningful. The use of appropriate cell lines as experimental models might provide guidance for translational breast cancer research.
Despite the aforementioned advantages, some technical limitations exist regarding our approach. Based on the predicted result, it is evident that the sum of the percentages of all subpopulations for each sample cannot reach 100%. Some unknown subpopulations will always exist in some studied samples. The deficiency might be owing to the shortage of methylation data available for breast cancer cell lines. Although a reasonable number of breast cancer cell lines are currently available to reflect the molecular subgroups, the existing cell lines did not explain all features observed in vivo because not all cancer cells were successfully cultured in vitro. Thus, it is defective that taking advantage of cells cultured in vitro to completely substitute the cell subpopulation in breast tissues in vivo. The development of single-cell sequencing and the identification of more cell types might solve this problem ideally. Following the analysis of more DNA methylation profiles and the identification of more cell types in breast cancer, our future work is expected to improve the performance of the method overcoming these limitations. Our deconvolution strategy might be suitable for use with whole-genome bisulphite sequencing data; if so, the method will identify more DNA methylation markers to deconvolve the population components in breast tissues. In the near future, this deconvolution process can be applied to other solid tumours owing to the development of sequencing technology.
Populations of tumour cells display remarkable variability in their genetic/epigenetic characteristics and morphology. Cancer cell subclones exhibit a great heterogeneity in DNA methylation, gene expression, germline variants and somatic mutations. In consequence, integrated analyses of multiple omics data containing DNA methylation, gene expression, miRNA expression, CNVs, SNVs and even histone modifications might be more accurate and persuasive for the evaluation of intra-tumour heterogeneity among cancers than the use of a single type of data. Currently, clinicians determine the therapeutic schedule and assess the prognosis of breast cancer patients based on ER, PR, HER2 and Ki67 results detection by immunohistochemical method [74] . Moreover, pathologists use strict criteria based on the tumour lymph node metastasis (TNM) classification to predict the clinical behaviour of malignancies [75] . Even though these criteria are widely used, they are deficient for use with highly heterogeneous breast cancer populations. Molecular technologies that are currently under development, such as the genomic, epigenomic and proteomic profiling of tumours, might improve the current TNM staging system. The organic combination of these clinical characteristics and molecular features might represent a major breakthrough in cancer heterogeneity research. For instance, analyses that combine a comprehensive portrait of primary and recurrent glioblastoma multiforme with molecular and clinical characteristics could aid the direction of potential targeted drug therapy [76] .
In conclusion, we present an unprecedented opportunity to infer cellular composition, including both the percentage of normal admixture and the proportions of several recognized tumour subpopulations, based on DNA methylation. This research strategy might be also appropriate for other malignancies, such as lung cancer or liver cancer, with minor revision. This study focused on the quantification of inter-and intra-tumour heterogeneity within a tumour mixture. Further analysis including the clinical and functional impact of the inferred tumour composition and corresponding proportions will play a crucial role in following work.
Key Points
• Heterogeneous cellular subpopulations within tumour tissues complicate diagnosis and can obstruct therapeutic decision-making.
• In this article, we summarized the cell-type-specific methylation signatures of established breast cancer cell lines and proposed a deconvolution strategy to address the cellular subclone population dynamics in cancer tissues.
• Great heterogeneity was found to exist in cancer populations and subgroups, which were redefined based on their discrepant cellular composition and proportions, resulting in different clinical characteristics and survival curves.
• This will be helpful for understanding intra-and inter-heterogeneity in relation to cancer evolution and provides new insights that might aid accurate diagnosis and individualized treatment.
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